In re Pfizer Inc. Shareholder Derivative Litigation,
No. 09-cv-7822 (S.D.N.Y.).

KM represented Skandia Life Insurance as counsel in securities derivative litigation against Pfizer in connection with Pfizer’s off-label promotion of its Bextra, Geodon, Zyvox and Lyrica drugs, for which it paid record civil and criminal fines, including the largest criminal fine in U.S. history. The litigation resulted in a $75 million settlement and numerous, significant changes to Pfizer’s corporate governance structure and compliance processes. Some of the changes made included the implementation of a Committee of the Board of Directors to oversee regulatory and compliance issues, external complaints regarding Pfizer's compliance, and compliance programs in newly acquired companies, and the establishment of an ombudsman program through which employees can surface complaints.